Study of Tofacitinib in Refractory Dermatomyositis: An Open‐Label Pilot Study of Ten Patients
Author:
Affiliation:
1. Johns Hopkins University School of Medicine Baltimore Maryland
2. Pfizer Inc. New York New York
Funder
Jerome L. Greene Foundation
National Institutes of Health
Pfizer
Publisher
Wiley
Subject
Immunology,Rheumatology,Immunology and Allergy
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41602
Reference22 articles.
1. A case of refractory dermatomyositis responsive to tofacitinib
2. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis
3. Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
4. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis
5. Polymyositis and Dermatomyositis
Cited by 104 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib;Journal of Dermatological Treatment;2024-08-27
2. Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons;Expert Opinion on Pharmacotherapy;2024-08-12
3. JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle;Life Science Alliance;2024-08-09
4. Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice;Best Practice & Research Clinical Rheumatology;2024-08
5. Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis;Rheumatology;2024-07-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3